# Intas Pharmaceuticals Limited - Inspection Records Source: https://www.globalkeysolutions.net/companies/intas-pharmaceuticals-limited/cfedbb2f-5587-42dc-985b-044083dd01e5 > Inspection records and compliance data for Intas Pharmaceuticals Limited in Ahmedabad, None. Access full analysis and detailed observations. --- ## Details - Name: Intas Pharmaceuticals Limited - FEI Number: 3004011473 - City: Ahmedabad - State: None - Country Name: India - Address Line 1: Plot No. 5 To 14, Pharmez, Near Village Matoda, Sarkhej-Bavla National Highway No. 8-A, Taluka, Sanand - Zip Code: None - Business Operations: API/FDF ANALYTICAL TESTING, FDF MANUFACTURE ## Related Documents - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #86995 - 2025-01-10](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/a42ae74b-82b5-49f2-9e79-940a4f77ceb4) — source: Canada, date: January 10, 2025 - [WARNING_LETTER - Intas Pharmaceuticals Limited - 2023-05-12](https://www.globalkeysolutions.net/records/warning_letter/intas-pharmaceuticals-limited/9e0758c3-e43d-4af6-8f19-a85862cedff3) — source: FDA, date: May 12, 2023 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #82079 - 2023-03-27](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/7514f741-e237-4c00-9ea2-889e5e7d82ac) — source: Canada, date: March 27, 2023 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #81637 - 2023-03-27](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/162d0885-8682-4601-9bba-e3fd3e5d7204) — source: Canada, date: March 27, 2023 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #82014 - 2023-01-10](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/a6325e9d-4773-4eb5-b038-2968d395d918) — source: Canada, date: January 10, 2023 - [483 - Intas Pharmaceuticals Limited - 2022-12-02](https://www.globalkeysolutions.net/records/483/intas-pharmaceuticals-limited/51f72db3-f323-4bb3-9458-0baa02a1227d) — source: FDA, date: December 2, 2022 - [WARNING_LETTER - Intas Pharmaceuticals Limited - 2022-12-02](https://www.globalkeysolutions.net/records/warning_letter/intas-pharmaceuticals-limited/69e72c80-0677-41df-92b7-50c9a9d7402e) — source: FDA, date: December 2, 2022 - [FDA Inspection 1191818 - Intas Pharmaceuticals Limited - 2022-12-02](https://www.globalkeysolutions.net/records/fda_inspections/intas-pharmaceuticals-limited/c40b512c-7d12-45b2-bbd7-edc2eba3727a) — classification: Official Action Indicated (OAI), source: FDA, date: December 2, 2022 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #80967 - 2022-09-03](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/0b33986e-da60-4dc8-a108-ff2224b98bd4) — source: Canada, date: September 3, 2022 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #80087 - 2022-06-06](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/9a894f32-549a-4132-8caa-7b0511f8c776) — source: Canada, date: June 6, 2022 - [483 - Intas Pharmaceuticals Limited - 2020-02-28](https://www.globalkeysolutions.net/records/483/intas-pharmaceuticals-limited/4840cbe4-0699-45d1-b557-35037fad9e93) — source: FDA, date: February 28, 2020 - [FDA Inspection 1119170 - Intas Pharmaceuticals Limited - 2020-02-28](https://www.globalkeysolutions.net/records/fda_inspections/intas-pharmaceuticals-limited/43470247-9a87-4de0-a9c2-c9ce8fac49f7) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 28, 2020 - [483 - Intas Pharmaceuticals Limited - 2019-05-28](https://www.globalkeysolutions.net/records/483/intas-pharmaceuticals-limited/ce617d78-cad5-4a6b-9b44-9d98421912d8) — source: FDA, date: May 28, 2019 - [FDA Inspection 1092798 - Intas Pharmaceuticals Limited - 2019-05-28](https://www.globalkeysolutions.net/records/fda_inspections/intas-pharmaceuticals-limited/5e800bc2-1d9a-499d-9ff0-7b46771cff99) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 28, 2019 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #74264 - 2019-05-20](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/72c61ca1-1bfc-4440-a0d4-a3676e212ac2) — source: Canada, date: May 20, 2019 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #70687 - 2018-01-29](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/59b26987-3635-4179-aac2-f0426b9821f1) — source: Canada, date: January 29, 2018 - [FDA Inspection 992746 - Intas Pharmaceuticals Limited - 2016-10-19](https://www.globalkeysolutions.net/records/fda_inspections/intas-pharmaceuticals-limited/a5863c26-41da-447a-b925-1bc399b01e2a) — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 19, 2016 - [FDA Inspection 910188 - Intas Pharmaceuticals Limited - 2014-12-19](https://www.globalkeysolutions.net/records/fda_inspections/intas-pharmaceuticals-limited/ecfd7d9b-83bb-4179-be43-4cc30e94f0e8) — classification: No Action Indicated (NAI), source: FDA, date: December 19, 2014 - [Canada Inspection - Intas Pharmaceuticals Limited - Inspection #18821 - 2014-12-11](https://www.globalkeysolutions.net/records/canada_inspection/intas-pharmaceuticals-limited/25c7d000-294c-424c-9d77-2cbf2be0f68a) — source: Canada, date: December 11, 2014 - [FDA Inspection 847008 - Intas Pharmaceuticals Limited - 2013-06-27](https://www.globalkeysolutions.net/records/fda_inspections/intas-pharmaceuticals-limited/2b1c7e62-59b2-4b67-9f2a-36f55b1ee69f) — classification: No Action Indicated (NAI), source: FDA, date: June 27, 2013 ## Related Companies - [Centaur Pharmaceuticals Private Limited](https://www.globalkeysolutions.net/companies/centaur-pharmaceuticals-private-limited/429667f3-78f8-45f1-b2ac-da0509f3e48d) - [Eugia Pharma Specialities Limited](https://www.globalkeysolutions.net/companies/eugia-pharma-specialities-limited/9733456f-3189-4fe6-a4f9-327f0ce92559) - [Apnar Pharma Private Limited](https://www.globalkeysolutions.net/companies/apnar-pharma-private-limited/14c28e0f-fd47-4c3a-80c3-f85e25d7ea0a) - [Italfarmaco S.A.](https://www.globalkeysolutions.net/companies/italfarmaco-sa/1c87038a-ed84-4bfa-bb11-1fd51ce8eacd) - [Elysium Pharmaceuticals Limited](https://www.globalkeysolutions.net/companies/elysium-pharmaceuticals-limited/6249fc41-1206-431f-87ee-b7b13c89e8f4) - [IntelliPharmaCeutics Corp.](https://www.globalkeysolutions.net/companies/intellipharmaceutics-corp/78f18be2-f4f4-44f4-88d7-30d9f8f36ac5) - [Pharmaceutics International Inc](https://www.globalkeysolutions.net/companies/pharmaceutics-international-inc/89d3a795-b80a-4c2b-81fe-20abd08cf281) - [Novel Laboratories, Inc. d.b.a Lupin Somerset](https://www.globalkeysolutions.net/companies/novel-laboratories-inc-dba-lupin-somerset/53a42119-c077-49fb-b739-db29c2b99391) - [Biocon Biologics Limited](https://www.globalkeysolutions.net/companies/biocon-biologics-limited/7eb84509-8dc4-4765-9a0e-d2f65781328d) - [Dr. Reddy's Laboratories Ltd.](https://www.globalkeysolutions.net/companies/dr-reddys-laboratories-ltd/3c6515a2-e42e-4803-ab0c-43955c67ee4f) ## Related Officers - [Massimilina G Dordunco](https://www.globalkeysolutions.net/people/massimilina-g-dordunco/286b35d8-e6f3-4930-a348-4791130ff98c) - [Patric C. Klotzbuecher](https://www.globalkeysolutions.net/people/patric-c-klotzbuecher/cbb2e6b5-b001-457e-9073-33535f02926e) - [Jennifer L. Huntington](https://www.globalkeysolutions.net/people/jennifer-l-huntington/c04e1c86-c7ec-4613-b3f7-a1f9ba2b2f2c) - [Pratik S. Upadhyay](https://www.globalkeysolutions.net/people/pratik-s-upadhyay/22ff2e0b-17d4-4c91-a3f0-c7e30b7a115b) - [Quality System Specialist](https://www.globalkeysolutions.net/people/jose-e-melendez/75bd6083-14a4-4bd2-a0e5-9946d4dd37e1)